FreeTheAI

Harmony Biosciences Names Peter Anastasiou as CEO Effective January 2027

NeutralMedium impact
HRMY$40.28 1.72%

Harmony Biosciences Holdings, Inc. (HRMY) has appointed Senior Executive Vice President and Chief Operating Officer Peter Anastasiou as its next President and Chief Executive Officer, effective January 1, 2027. Anastasiou will also join the board of directors. He succeeds Jeffrey M. Dayno, M.D., who will retire at the end of 2026 following nine years with the company. Dayno will stay on as a non-executive advisor through 2027 to assist with the transition.

The leadership succession comes as the pharmaceutical company expands its central nervous system portfolio. Alongside the leadership announcement, management reiterated its full-year 2026 net revenue guidance for WAKIX of $1.0 billion to $1.04 billion. The firm stated that its corporate strategy, balance sheet, and commercial objectives remain on track without shifts in key timeline targets.

Investors will look to upcoming research updates as the next operational milestone. The company remains on schedule to report data from its multiple ascending dose clinical study of BP-205 in the fourth quarter of 2026.

Key points

  • Peter Anastasiou will become President, CEO, and a board member of Harmony Biosciences on January 1, 2027.
  • Current CEO Jeffrey M. Dayno, M.D., will retire on December 31, 2026, and serve as a non-executive advisor through 2027.
  • Harmony Biosciences reiterated its full-year 2026 net revenue guidance for WAKIX of $1.0 billion to $1.04 billion.
  • The company expects to report clinical study data for BP-205 in the fourth quarter of 2026.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Who is the new CEO of Harmony Biosciences?

Peter Anastasiou, current Chief Operating Officer and former board member, has been appointed President and CEO effective January 1, 2027.

When does CEO Jeffrey M. Dayno step down?

Jeffrey M. Dayno, M.D., will retire as President and CEO on December 31, 2026, and will serve as a non-executive advisor throughout 2027.

What is Harmony Biosciences' 2026 WAKIX revenue guidance?

Harmony Biosciences reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.